Canadian Immunization conference

13 November 2018

The ongoing occurrence of vaccine-preventable disease outbreaks makes CIC 2018 an important venue to discuss the recurrence and emergence of infectious diseases that are posing challenges for public health at all levels. Critical to our degree of preparedness are an ability to continue to develop and improve vaccines, strengthen public health surveillance systems, and support timely and practice-relevant immunization program research, as well as an encouraging of evidence-based and ethical policy and practice measures to help us better control infectious diseases and improve public confidence in vaccines.

From December 4–8, 2018, over 900 delegates will connect, collaborate, share and learn. The innovative scientific program will engage and inspire future research, policies and practices. To facilitate knowledge exchange and engagement, the Organizing Committee engages with experts and thought-provoking speakers who will inspire and challenge delegates.

Practical informations
4-6 December 2018
Canadian Public Health Association
Ottawa, Canada

Related News & Events

  • 6 -7

    Global NITAG Network Meeting

    WHO & Public Health Agency of Canada
    Shaw Centre in Ottawa, Canada
  • Canada

    NACI mandate expands to support local decision-making on vaccine programs


    In June 2016 the Public Health Agency of Canada (PHAC) announced that the mandate of Canada’s NITAG, the National Advisory Committee on Immunization (NACI) will be expanded. In addition to the assessment of vaccine characteristics (safety, efficacy, effectiveness, and immunogenicity), NACI will also be assessing additional programmatic elements including economic evaluations, feasibility of implementation, acceptability, ethics and equity. 

    Read more
  • Canada

    Introducing NACI newest recommendations regarding the use of Hepatitis B vaccine


    NACI have released the update on the recommended use of Hepatitis B vaccine. It includes 4 main recommendations:

    1. NACI does not recommend routine booster doses of HB vaccine for immunocompetent individuals following the completion of a recommended HB immunization schedule given in infancy.
    2. NACI recommends that adults with diabetes need not be considered as a separate high risk group for immunization with HB vaccine.
    3. For immunocompromised individuals, initial annual monitoring of HB antibody levels following HB immunization may be considered
    4. Immunization with HB-containing vaccine should be provided according to determined provincial and territorial (P/T) schedules.
    Read more